Tempest Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated November 8, 2023, serves as a current report for Tempest Therapeutics, Inc. (TPST). The filing announces the Company's financial results for the quarter ended September 30, 2023, by incorporating a press release as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the referenced press release (Exhibit 99.1) which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of the Q3 2023 results announcement.
Guidance, Outlook, and Risks
The filing references a press release titled "Tempest Reports Third Quarter 2023 Financial Results and Provides Corporate Highlights." However, the text of this 8-K does not explicitly state the guidance, outlook, management commentary, risks, or unusual items contained within that press release.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific Q3 2023 financial figures.
- Verify the Company's cash runway and burn rate as disclosed in the referenced exhibit.
- Confirm any updates to clinical trial timelines or corporate highlights mentioned in the press release.
- Check for any forward-looking statements or revised guidance provided in the November 8, 2023 announcement.